{
    "clinical_study": {
        "@rank": "92405", 
        "arm_group": [
            {
                "arm_group_label": "Metformin-Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Metformin, 2x 2 tablets a day, 500 mg tablets for 12 weeks, 6 weeks wash-out, 12 weeks placebo"
            }, 
            {
                "arm_group_label": "Placebo-metformin", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo tablets, 2x 2 tablets per day for 12 weeks, 6 weeks wash-out, 12 weeks metformin, 2x 2 tablets per day, 500 mg per tablet"
            }
        ], 
        "brief_summary": {
            "textblock": "This study investigates the incretin effect in women with polycystic ovary syndrome (PCOS)\n      before and after removal of their insulin resistance by metformin.\n\n      The investigators' hypothesis is that insulin resistant women with PCOS have a reduced\n      incretin effect and elevated glucagon responses as measured by a 75-g oral glucose tolerance\n      test and isoglycemic i.v. glucose infusion. The investigators hypothesise that both can be\n      improved when their insulin resistance is removed."
        }, 
        "brief_title": "Incretin Effect in PCOS Women", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Polycystic Ovary Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Insulin Resistance", 
                "Polycystic Ovary Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria PCOS-women:\n\n          -  Diagnosed with PCOS according to the Rotterdam criteria\n\n          -  more than 18 years old\n\n          -  BMI less than 30 kg/m2\n\n          -  Normal glucose tolerance and fasting plasma glucose (assessed by 75-g OGTT)\n\n          -  Negative GAD65 and islet cell autoantibodies\n\n          -  Insulin resistant according to HOMA-IR\n\n          -  informed consent\n\n        Inclusion Criteria healthy women:\n\n          -  more than 18 years old\n\n          -  BMI less than 30 kg/m2\n\n          -  Normal glucose tolerance and fasting plasma glucose (assessed by 75-g OGTT)\n\n          -  Negative GAD65 and islet cell autoantibodies\n\n          -  informed consent\n\n          -  regular menstrual cycle (28-35 days)\n\n          -  Plasma androgen levels within reference levels\n\n        Exclusion Criteria PCOS and healthy women:\n\n          -  First or second degree relatives with diabetes\n\n          -  pregnancy or breast feeding\n\n          -  treatment with medication which influences the glucose metabolism (incl hormonal\n             contraception)\n\n          -  Congenital diseases which cause hyperandrogenism and irregular bleeding\n\n          -  Known adrenal hyperplasia\n\n          -  Known hyperprolaktinemia\n\n          -  Alcohol consumption of more than 20 grams a day\n\n          -  Hemoglobin less than 7.8 %"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01892254", 
            "org_study_id": "PCOS-INK"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Metformin-Placebo", 
                    "Placebo-metformin"
                ], 
                "description": "Metformin, 2x 2 tablets a day, 500 mg tablets", 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Metformin-Placebo", 
                    "Placebo-metformin"
                ], 
                "description": "Placebo (to metformin)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Metformin", 
                "Incretins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "incretin effect", 
            "PCOS", 
            "insulin resistance", 
            "OGTT", 
            "IIGI"
        ], 
        "lastchanged_date": "June 30, 2013", 
        "location": {
            "contact": {
                "email": "Louise.Vedtofte@regionh.dk", 
                "last_name": "Louise Vedtofte, Cand.scient., PhD", 
                "phone": "+45 39772688"
            }, 
            "facility": {
                "address": {
                    "city": "Hellerup", 
                    "country": "Denmark", 
                    "state": "Select a State", 
                    "zip": "2900"
                }, 
                "name": "Copenhagen University Hospital Gentofte"
            }, 
            "investigator": {
                "last_name": "Louise Vedtofte, Cand.scient., PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "2", 
        "official_title": "Inkretineffekten Hos Patienter Med Polycystisk Ovariesyndrom f\u00f8r og Efter Behandling af Insulinresistens (Incretin Effect in Patients With Polycystic Ovary Syndrome Before and After Treatment of Insulin Resistance)", 
        "overall_contact": {
            "email": "Louise.Vedtofte@regionh.dk", 
            "last_name": "Louise Vedtofte, Cand.Scient., PhD", 
            "phone": "+45 39772688"
        }, 
        "overall_contact_backup": {
            "email": "signe.foghsgaard@regionh.dk", 
            "last_name": "Signe Foghsgaard, MD", 
            "phone": "+45 39772302"
        }, 
        "overall_official": {
            "affiliation": "Copenhagen University Hospital Gentofte", 
            "last_name": "Louise Vedtofte, Cand.scient., PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Denmark: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The incretin effect will be assessed from the insulin secretion during af 75 g OGTT and IIGI at baseline and after 12 weeks' treatment with placebo and metformin", 
            "measure": "The change in incretin effect from baseline and until after removal of insulin resistance", 
            "safety_issue": "No", 
            "time_frame": "baseline and 12 weeks' treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01892254"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Hospital, Gentofte, Copenhagen", 
            "investigator_full_name": "Louise Vedtofte", 
            "investigator_title": "Humanbiolog, ph.d.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Glucagon responses (plasma concentrations) will be assessed during the 75-g OGTTs", 
            "measure": "Glucagon response", 
            "safety_issue": "No", 
            "time_frame": "0, 12 and 30 weeks"
        }, 
        "source": "University Hospital, Gentofte, Copenhagen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Gentofte, Copenhagen", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}